Abstract
The excessive contraction of small arteries under high blood pressure is the main contributor to the pathological change of hypertension. Current anti-hypertensive drugs, which lack a selective effect on small arteries in a hypertensive state, may cause many adverse effects. We have developed a novel opener of ATP-sensitive potassium channels, iptakalim, the vasorelaxing action of which is determined by the hypertensive status of small arteries. In conscious strokeprone, spontaneously hypertensive rats and “two-kidneys, one-clip” renal hypertensive dogs, this compound produced long-lasting hypotensive effects, with no tolerance. Furthermore, it exerted a protective effect against hypertensive damage to target organs. Given its potency and fewer side effects, iptakalim hydrochloride is a promising drug for the treatment of hypertension.
Keywords: hypertension, atp-sensitive potassium channel, iptakalim, small artery, vasodilator, side effects, selective hypotensive efficacy, cardiovascular remodeling
Current Vascular Pharmacology
Title: Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers
Volume: 3 Issue: 2
Author(s): Hai Wang, Ying-Li Zhang and Yu-Ping Chen
Affiliation:
Keywords: hypertension, atp-sensitive potassium channel, iptakalim, small artery, vasodilator, side effects, selective hypotensive efficacy, cardiovascular remodeling
Abstract: The excessive contraction of small arteries under high blood pressure is the main contributor to the pathological change of hypertension. Current anti-hypertensive drugs, which lack a selective effect on small arteries in a hypertensive state, may cause many adverse effects. We have developed a novel opener of ATP-sensitive potassium channels, iptakalim, the vasorelaxing action of which is determined by the hypertensive status of small arteries. In conscious strokeprone, spontaneously hypertensive rats and “two-kidneys, one-clip” renal hypertensive dogs, this compound produced long-lasting hypotensive effects, with no tolerance. Furthermore, it exerted a protective effect against hypertensive damage to target organs. Given its potency and fewer side effects, iptakalim hydrochloride is a promising drug for the treatment of hypertension.
Export Options
About this article
Cite this article as:
Wang Hai, Zhang Ying-Li and Chen Yu-Ping, Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers, Current Vascular Pharmacology 2005; 3 (2) . https://dx.doi.org/10.2174/1570161053586895
DOI https://dx.doi.org/10.2174/1570161053586895 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture Levosimendan for Heart-Operated Patients: What is the State of the Art?
Recent Patents on Cardiovascular Drug Discovery L-Arginine Transport and Nitric Oxide Production in Kinin Receptor B1-/- Endothelial Cells.
Protein & Peptide Letters News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines
Current Drug Metabolism Treatment of Pulmonary Thromboembolism in Patients with Systemic Blood Pressure Stability and Right Ventricular Dysfunction
Current Respiratory Medicine Reviews Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Food Allergy
Current Pharmaceutical Design Review of Rational Approaches to the Treatment of Pain Management-Role forOpioids Therapies
Current Drug Therapy Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Reduction of Myocardial Ischemia-Reperfusion Injury with Pre- and Postconditioning: Molecular Mechanisms and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends
Current Vascular Pharmacology